Prostatype Genomics AB (publ) (PROGEN.ST)

SEK 10.3

(-8.04%)

Long Term Debt Summary of Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)'s latest annual long term debt in 2023 was 67 Thousand SEK , down -85.64% from previous year.
Prostatype Genomics AB (publ)'s latest quarterly long term debt in 2024 Q1 was - SEK , down -100.0% from previous quarter.
Prostatype Genomics AB (publ) reported annual long term debt of 466.66 Thousand SEK in 2022, down -46.15% from previous year.
Prostatype Genomics AB (publ) reported annual long term debt of 866.66 Thousand SEK in 2021, down -18.75% from previous year.
Prostatype Genomics AB (publ) reported quarterly long term debt of - SEK for 2024 Q2, down 0.0% from previous quarter.
Prostatype Genomics AB (publ) reported quarterly long term debt of 67 Thousand SEK for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Prostatype Genomics AB (publ) (2023 - 2015)

Historical Annual Long Term Debt of Prostatype Genomics AB (publ) (2023 - 2015)

Year	Long Term Debt	Long Term Debt Growth
2023	67 Thousand SEK	-85.64%
2022	466.66 Thousand SEK	-46.15%
2021	866.66 Thousand SEK	-18.75%
2020	1.06 Million SEK	0.0%
2018	6.45 Million SEK	-32.44%
2017	9.55 Million SEK	371.36%
2016	2.02 Million SEK	-47.55%
2015	3.86 Million SEK	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	- SEK	-100.0%
2024 Q2	- SEK	0.0%
2023 Q4	67 Thousand SEK	0.0%
2023 FY	67 Thousand SEK	-85.64%
2023 Q3	67 Thousand SEK	-74.85%
2023 Q2	266.41 Thousand SEK	-27.29%
2023 Q1	366.41 Thousand SEK	-21.48%
2022 Q4	466.66 Thousand SEK	-17.65%
2022 Q3	566.66 Thousand SEK	-34.62%
2022 FY	466.66 Thousand SEK	-46.15%
2022 Q2	866.66 Thousand SEK	0.0%
2022 Q1	866.66 Thousand SEK	0.0%
2021 FY	866.66 Thousand SEK	-18.75%
2021 Q2	1.06 Million SEK	0.0%
2021 Q1	1.06 Million SEK	0.0%
2021 Q4	866.66 Thousand SEK	-18.75%
2021 Q3	1.06 Million SEK	0.0%
2020 Q3	5.25 Million SEK	-3.39%
2020 Q2	5.43 Million SEK	0.0%
2020 FY	1.06 Million SEK	0.0%
2020 Q4	1.06 Million SEK	-79.69%
2019 Q3	1.46 Million SEK	0.0%
2018 FY	6.45 Million SEK	-32.44%
2017 FY	9.55 Million SEK	371.36%
2016 FY	2.02 Million SEK	-47.55%
2015 FY	3.86 Million SEK	0.0%

Peer Long Term Debt Comparison of Prostatype Genomics AB (publ)

Name	Long Term Debt	Long Term Debt Difference
AroCell AB (publ)	- SEK	-Infinity%
Devyser Diagnostics AB (publ)	600 Thousand SEK	88.833%
Immunovia AB (publ)	1.78 Million SEK	96.251%
SenzaGen AB	1.67 Million SEK	95.995%
Spermosens AB	230 Thousand SEK	70.87%